EUCTR2006-001999-20-HUActive, not recruitingNot Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 270
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Male or female subjects with papulo-pustular rosacea with at least 15 inflammatory facial lesions, at least 18 years old, meeting specific inclusion and exclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, and secondary rosacea form, isolated erythrosis, isolated rhinophyma, or isolated pustulosis of the chin),
- •2. The subject has other dermatological disorders such as peri-oral dermatitis, other forms of demodicidosis, facial keratosis pilaris, actual or history of seborrheic dermatitis, which may confound the study assessments,
Investigators
Similar Trials
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-CZGalderma Research & Development SNC270
Active, not recruiting
Not Applicable
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-DEGalderma Research & Development SNC274
Not yet recruiting
Not Applicable
COMPARING SAFETY AND EFFICACY OF 3 DIFFERENT DOSES OF FENTANYL TO HEMODYNAMIC STRESS RESPONSE TO LARYNGOSCOPY AND INTUBATIOCTRI/2021/07/035113DEPARTMENT OF ANESTHESIOLOGY
Active, not recruiting
Phase 1
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBVChronic Hepatitis C Virus Infection (Genotype 1, 2, 3, 4)MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003463-22-FRBristol-Myers Squibb International Corporation71
Not yet recruiting
Phase 2
Evaluation and comparison of the efficacy of triple therapies regimens containing esomeprazole and different doses of amoxicillin and bismuth for eradicating Helicobacter pylori infection in SariIRCT20210518051335N1Mazandaran University of Medical Sciences200